Bind Therapeutics Company Profile (NASDAQ:BIND)

Analyst Ratings

Consensus Ratings for Bind Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $7.44 (785.42% upside)

Analysts' Ratings History for Bind Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Oppenheimer Holdings Inc.DowngradeMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$9.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$20.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Bind Therapeutics (NASDAQ:BIND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q116($0.55)($0.61)$3.83 million$1.87 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.49)($0.37)$3.35 million$6.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q315($0.52)($0.49)$3.14 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.51)($0.51)$3.88 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.51)($0.44)$2.67 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.40)($0.51)$6.00 million$3.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.31)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.60)($0.51)$2.20 million$2.46 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014($0.49)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014($0.41)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.67)($2.70)$1.66 million$4.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bind Therapeutics (NASDAQ:BIND)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.61)($0.58)($0.60)
Q2 20162($0.48)($0.46)($0.47)
Q3 20162($0.48)($0.46)($0.47)
Q4 20162($0.49)($0.47)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bind Therapeutics (NASDAQ:BIND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bind Therapeutics (NASDAQ:BIND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/25/2013Noubar AfeyanDirectorBuy20,000$15.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2013Polaris Venture Management Co.Major ShareholderBuy26,000$15.00$390,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bind Therapeutics (NASDAQ:BIND)
DateHeadline
07/27/16 08:36 PMPfizer Cleared to Buy Nanotech Drug Firm Bind Therapeutics
07/27/16 08:36 PMBind Therapeutics Wins OK Of $40M Ch. 11 Sale to Pfizer
07/27/16 11:55 AM[$$] Pfizer Cleared to Buy Nanotech Drug Firm Bind Therapeutics -
07/27/16 11:20 AMSirius XM Holdings Inc. (NASDAQ:SIRI) & BIND Therapeutics (NASDAQ:BIND) Active Stock's Momentum - Money News (press release)
07/27/16 11:20 AMBRIEF-Bind Therapeutics determines Pfizer's $40 mln bid highest - Reuters
07/27/16 11:20 AMBind Therapeutics seeks court approval for $40m Pfizer bid - The Boston Globe
07/26/16 08:48 PMNasdaq Composite Index May Have Diverged from Reality (Over-Bought?)
07/26/16 08:48 PMU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.10%
07/26/16 08:48 PMBIND Therapeutics (BIND) Determines Pfizer's $40M Bid is Highest and Best
07/26/16 08:48 PMBIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets
07/26/16 04:48 PMBIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets - [at noodls] - July 26, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that ...
07/26/16 02:42 PMStock Performance to Track: BIND Therapeutics, Inc. (NASDAQ:BIND) - News Oracle
07/26/16 02:42 PMBIND Therapeutics Inc (NASDAQ:BIND) Shareholders Are On Borrowed Time; Don't Get Caught Out - Insider Financial
07/26/16 10:26 AMIntraday Active Biotech Stocks News: BIND Therapeutics, Inc. (NASDAQ:BIND), Tobira Therapeutics, Inc. (NASDAQ ... - The Voice Registrar
07/25/16 03:21 PMBIND Therapeutics Announces Two Bidders Join Pfizer's Stalking ... - Business Wire (press release)
07/25/16 07:36 AMBIND Therapeutics (BIND) Announces Receipt of Two Competing Bids (PFE)
07/25/16 07:36 AMBIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets
07/25/16 06:58 AMBIND Therapeutics Announces Two Bidders Join Pfizer's Stalking Horse Bid in Auction for BIND's Assets - [at noodls] - July 25, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that ...
07/23/16 02:47 PMShares Stumbling of Late: BIND Therapeutics, Inc. (NASDAQ:BIND) - TGP
07/23/16 07:04 AMEquity Roundup: Stock Performance Focus on BIND Therapeutics, Inc. (NASDAQ:BIND) - Press Telegraph
07/22/16 11:02 AMNanoparticles Transforming Future of Novel Drug Delivery Systems in Cancer Therapy Market, says TMR
07/21/16 11:20 AMBIND Therapeutics, Inc. (NASDAQ:BIND) Current Analyst Ratings - Fiscal Standard
07/20/16 09:44 PMBind Therapeutics Incorporated (NASDAQ:BIND) Shorts Decreased by 75.83% After Short Covering - Consumer Eagle
07/20/16 09:44 PMBIND Therapeutics, Inc. (NASDAQ:BIND): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/17/16 07:33 AMShares Moving Down on the Week: BIND Therapeutics, Inc. (NASDAQ:BIND) - Engelwood Daily
07/17/16 07:33 AMBIND Therapeutics, Inc. (NASDAQ:BIND) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 02:49 PMAre Analysts Bullish BIND Therapeutics Inc (NASDAQ:BIND) After Last Week? - Consumer Eagle
07/13/16 08:15 PMBIND Therapeutics, Inc. (NASDAQ:BIND) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 10:55 AMBIND Therapeutics, Inc. (NASDAQ:BIND) plummeted -7.41%: Vale S.A. (NYSE:VALE), Jacksonville Bancorp Inc ... - KC Register
07/13/16 10:55 AMBIND Therapeutics, Inc. (NASDAQ:BIND) Updated Price Targets - FTSE News
07/12/16 08:18 PMBind Therapeutics Inc (NASDAQ:BIND) Q1 2016 Sentiment - Press Telegraph
07/12/16 02:54 PMKidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 - New Market Report
07/11/16 02:49 PMWhere Does BIND Therapeutics Inc (NASDAQ:BIND)'S Asset Deal With Pfizer (PFE) Leave Its Other Partners? - Market Exclusive
07/11/16 07:39 AMWall Street Ratings and Target Price Views on BIND Therapeutics, Inc. (NASDAQ:BIND) - Telanagana Press
07/10/16 07:33 AMNext Weeks Broker Price Targets For BIND Therapeutics, Inc. (NASDAQ:BIND) - Fiscal Standard
07/09/16 02:43 PMBind Therapeutics Incorporated (NASDAQ:BIND) Sellers Increased By 5.3% Their Shorts - Press Telegraph
07/07/16 10:46 AMUnusual Volume Recap: BIND Therapeutics, Inc. (NASDAQ:BIND) - Engelwood Daily
07/07/16 10:46 AMCan BIND Therapeutics, Inc. (NASDAQ:BIND) Improve on the Earnings Front? - Engelwood Daily
07/07/16 10:46 AMAnalyst Buzz: BIND Therapeutics, Inc. (NASDAQ:BIND) - News Oracle
07/07/16 10:46 AMPfizer makes 'stalking horse' bankruptcy bid for Bind Therapeutics - The Boston Globe
07/06/16 08:39 PMFrance woos business from UK with tax breaks and English
07/06/16 02:54 PMPfizer makes bid for Bind after repayment woes
07/06/16 02:54 PMPfizer makes ‘stalking horse’ bankruptcy bid for Bind Therapeutics
07/06/16 08:20 AM[$$] Pfizer Offers $20 Million for Bind Therapeutics Assets -
07/06/16 07:39 AMBIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer
07/06/16 07:39 AMBIND Therapeutics Pulls Back Off Best Levels But Remains Firmly Positive
07/06/16 07:39 AMPfizer Offers $20 Million for Bind Therapeutics Assets
07/06/16 07:01 AMBIND THERAPEUTICS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statem -
07/05/16 02:51 PMBind Therapeutics Incorporated (NASDAQ:BIND) Short Interest Increased By 5.3% - Press Telegraph
07/01/16 04:51 PMBIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc. - [at noodls] - July 1, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS, today announced it has ...

Social

About Bind Therapeutics

Bind Therapeutics logoBIND Therapeutics, Inc. is a biotechnology company. The Company is engaged in developing targeted therapeutics, primarily for the treatment of cancer. The Company's product candidates are based on polymeric nanoparticles called ACCURINS, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS are polymeric nanoparticles that incorporate therapeutic payloads with diverse physical and chemical properties, provide prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. Its drug candidate, BIND-014, which has entered clinical development, is a prostate specific membrane antigen (PSMA)-targeted ACCURIN that contains docetaxel, a clinically validated cancer chemotherapy drug. It designs ACCURINS with specific pharmaceutical properties intended to target tumors at approximately three levels, such as tissue, cellular and molecular.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIND
  • CUSIP:
Key Metrics:
  • Previous Close: $0.84
  • 50 Day Moving Average: $0.49
  • 200 Day Moving Average: $1.18
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $17.54M
  • Beta: 2.02
  • Current Year EPS Consensus Estimate: $-1.47 EPS
  • Next Year EPS Consensus Estimate: $-1.42 EPS
Additional Links:
Bind Therapeutics (NASDAQ:BIND) Chart for Thursday, July, 28, 2016